NDAINJECTIONINJECTABLEPriority Review
Approved
Sep 1995
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
6
Mechanism of Action
2 major pharmacological actions: (1) direct vasodilation of pulmonary and systemic arterial vascular beds and (2) inhibition of platelet aggregation.
Clinical Trials (5)
Evaluation of a New Thermostable Formulation of FLOLAN in Japanese Subjects
Started May 2016
10 enrolled
Cardiovascular Disease
Study of a New Thermo Stable Formulation of Epoprostenol Sodium to Treat Pulmonary Arterial Hypertension (PAH)
Started Nov 2011
16 enrolled
Hypertension, Pulmonary
Rapid Switch From Flolan to Remodulin in the Outpatient Clinic
Started Mar 2008
7 enrolled
Hypertension, Pulmonary
Safety, Efficacy, and Treatment Satisfaction Switching From Flolan to Remodulin Using the Crono Five Ambulatory Pump in Patients With PAH
Started Feb 2007
8 enrolled
Pulmonary Arterial Hypertension
A Transition Study From Flolan® to Remodulin® in Patients With Pulmonary Arterial Hypertension
Started Oct 2002
39 enrolled
Pulmonary Arterial HypertensionPulmonary Hypertension